 AUSTIN, Texas, July 2, 2021 PRNewswire -- Natera, Inc. NASDAQ: NTRA, a pioneer and global leader in cell-free DNA testing, today announced it will present new data on its personalized and tumor-informed molecular residual disease MRD assay, Signatera, at the 2021 European Society for Medical Oncology World Congress on Gastrointestinal Cancer ESMO GI, taking place June 30 - July 3, 2021. Data will be presented in colorectal cancer CRC and pancreatic cancer. 